IISG has developed a strong portfolio of next-generation antibody therapies to treat a spectrum of cancer indications
via targeting multiple intracellular oncoproteins.
* Additional Phase 2 HSA approved trial ongoing in Singapore NCC
** Additional Phase 2 HSA approved trial ongoing in Singapore NCC
Milestones
2008
new concept on Cancer Immunotherapy
2017
Phase I clinical trial in Singapore
2019
Phase II clinical trial in Singapore
2020
Phase II clinical trial in USA
2021
Phase II clinical trial in CHINA
